



























































- Biomarker testing connects patients with the most effective treatments.
- Research shows that biomarker-driven treatments can **improve health outcomes**, **increase quality of life**, and prolong patient survival.
- Ineffective treatments exacerbate the physical, emotional, and economic burdens of disease, and the price is paid by both the patient and the insurer.

Comparable legislation has passed with overwhelming bipartisan support and signed into law in nine states: Arizona, Arkansas, Georgia, Illinois, Kentucky, Louisiana, Maryland, New Mexico, and Rhode Island.

Insurance coverage for needed biomarker testing is failing to keep pace with innovations and advancements in treatment. We must work to remove barriers to biomarker testing to ensure that patients can unlock the value and cost-saving potential of precision medicine.

If you have any questions about this legislation or biomarker testing more generally, please reach out to Hilary Gee Goeckner at hilary.gee@cancer.org.

ALS Association

American Cancer Society Cancer Action

Network

American Lung Association

American Kidney Fund

Arthritis Foundation

Be the Match/National Marrow Donor

Program

Cancer Support Community

Exon 20 Group

Fight Colorectal Cancer

Global Colon Cancer Association

Go2 for Lung Cancer

Head and Neck Cancer Alliance

HEAL Collaborative

International Foundation for Autoimmune &

Autoinflammatory Arthritis (AIA)

ICAN, International Cancer Advocacy Network

Infusion Access Foundation

KRAS Kickers

Lung Cancer Research Foundation

LUNGevity Foundation

Lupus and Allied Diseases Association, Inc.

National Comprehensive Cancer Network

(NCCN)

National Organization for Rare Diseases

National Ovarian Cancer Coalition

Oncology Nursing Society

Patients Rising

Susan G. Komen

TargetCancer Foundation

Triage Cancer

Zero - The End of Prostate Cancer